Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Loxo Oncology CS (LOXO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,182,943
  • Shares Outstanding, K 30,615
  • Annual Sales, $ 21,300 K
  • Annual Income, $ -148,880 K
  • 36-Month Beta 2.51
  • Price/Sales 48.88
  • Price/Cash Flow N/A
  • Price/Book 18.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -1.16
  • Number of Estimates 8
  • High Estimate -0.56
  • Low Estimate -2.47
  • Prior Year -0.69
  • Growth Rate Est. (year over year) -68.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
233.14 +0.71%
on 01/16/19
234.93 -0.06%
on 02/13/19
+1.13 (+0.48%)
since 01/15/19
3-Month
125.00 +87.84%
on 12/24/18
234.93 -0.06%
on 02/13/19
+83.27 (+54.95%)
since 11/15/18
52-Week
103.50 +126.86%
on 02/20/18
234.93 -0.06%
on 02/13/19
+129.83 (+123.68%)
since 02/15/18

Most Recent Stories

More News
Lilly Completes Acquisition of Loxo Oncology

Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into...

LLY : 122.48 (+1.43%)
LOXO : 234.80 (+0.06%)
5 Tiny Biotech Stocks With Superb Growth Potential

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

CLDX : 5.86 (+13.35%)
CYTK : 7.90 (+3.67%)
CELG : 90.69 (+0.01%)
AEZS : 3.93 (-2.72%)
BDSI : 4.63 (+3.12%)
LLY : 122.48 (+1.43%)
LOXO : 234.80 (+0.06%)
ADRO : 4.05 (+10.05%)
BMY : 51.67 (+1.65%)
TAK : 20.46 (+1.74%)
Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

LLY : 122.48 (+1.43%)
LOXO : 234.80 (+0.06%)
TEVA : 17.98 (+4.05%)
AMGN : 188.34 (+0.89%)
Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology

Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2018.

LLY : 122.48 (+1.43%)
LOXO : 234.80 (+0.06%)
Is the Options Market Predicting a Spike in Loxo Oncology (LOXO) Stock?

Investors need to pay close attention to Loxo Oncology (LOXO) stock based on the movements in the options market lately.

LOXO : 234.80 (+0.06%)
5 Best Biotech Bets Likely to Outperform Estimates in Q4

Let us take a look at five promising biotech stocks for the fourth quarter of 2018.

CELG : 90.69 (+0.01%)
BLUE : 137.03 (+2.04%)
LLY : 122.48 (+1.43%)
ALNY : 83.53 (+0.60%)
LOXO : 234.80 (+0.06%)
REGN : 423.97 (+2.17%)
AMGN : 188.34 (+0.89%)
BMY : 51.67 (+1.65%)
Shares of Biogen Inc Rank the Highest in Terms of Relative Performance in the Biotechnology Industry (BIIB , CARA , LOXO , CELG , GILD )

Below are the top five companies in the Biotechnology industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that have the...

CARA : 17.05 (+3.02%)
LOXO : 234.80 (+0.06%)
BIIB : 332.87 (+2.51%)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders

The following statement is being issued by Levi & Korsinsky, LLP:

LLY : 122.48 (+1.43%)
LOXO : 234.80 (+0.06%)
INVESTOR ALERT: Monteverde & Associates PC is Investigating the Recently Announced Merger

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating:

OHI : 36.46 (-0.74%)
CELG : 90.69 (+0.01%)
OHRP : 2.11 (-0.94%)
MB : 36.46 (-0.05%)
LOXO : 234.80 (+0.06%)
HFBC : 19.82 (+0.51%)
MRT : 10.80 (-0.37%)
Financialinsiders.com: 'Indexes Rise' Market News Recap Week Ending January 11th, 2019

U.S. stocks continued their climb throughout the week, lifted by ongoing trade discussions between the U.S. and China. Investors seemed optimistic about the talks, especially after U.S. President Donald...

TGT : 72.84 (+0.91%)
UNP : 170.24 (+0.36%)
LLY : 122.48 (+1.43%)
LOXO : 234.80 (+0.06%)
KSS : 65.93 (-0.15%)
AAL : 35.05 (-2.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade LOXO with:

Business Summary

Loxo Oncology, Inc. is a biopharmaceutical company. It develops targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Loxo Oncology, Inc. is headquartered in Stamford, Connecticut.

See More

Key Turning Points

2nd Resistance Point 234.95
1st Resistance Point 234.81
Last Price 234.80
1st Support Level 234.59
2nd Support Level 234.51

See More

52-Week High 234.93
Last Price 234.80
Fibonacci 61.8% 184.72
Fibonacci 50% 169.21
Fibonacci 38.2% 153.71
52-Week Low 103.50

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar